0 773

Cited 16 times in

Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea

DC Field Value Language
dc.contributor.author안상훈-
dc.contributor.author한광협-
dc.contributor.author한규연-
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author김자경-
dc.contributor.author김현창-
dc.contributor.author박윤혜-
dc.contributor.author박준용-
dc.contributor.author신승환-
dc.date.accessioned2015-01-06T16:52:34Z-
dc.date.available2015-01-06T16:52:34Z-
dc.date.issued2014-
dc.identifier.issn0815-9319-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/98939-
dc.description.abstractBACKGROUND AND AIMS: Chronic hepatitis B (CHB) can progress to cirrhosis, hepatocellular carcinoma (HCC), and ultimately liver-related deaths. Recently, owing to potent antiviral therapy with minimal side-effects, sustained suppression of hepatitis B virus replication can be achieved, thereby preventing such complications. We aimed to reappraise clinical courses regarding disease progression in the era of antiviral therapy. METHODS: Between 2001 and 2005, treatment-naïve Korean CHB patients without cirrhosis were enrolled and followed up for at least 5 years. During follow up, antiviral therapy was commenced according to Korean Association for the Study of the Liver guidelines, if eligible, and ultrasonography and laboratory and clinical assessment were performed regularly. Primary end-points were development of cirrhosis, hepatic decompensation, HCC, or liver-related deaths. RESULTS: Of 360 patients, 323 (89.7%) received antiviral therapy such as lamivudine (70.6%), entecavir (8.7%), or telbivudine (6.5%). During follow up, cirrhosis developed in 29 (8.1%), hepatic decompensation in 4 (1.1%), and HCC in 15 (4.2%) patients. Annual incidences of cirrhosis, hepatic decompensation, and HCC were 1.05%, 0.14%, and 0.53% per person-year, respectively. Age was an independent predictor for developing cirrhosis (hazard ratio [HR] 1.075, 95% confidence interval [CI] 1.037-1.116; P < 0.001), whereas age (HR 1.060, 95% CI 1.012-1.111; P = 0.014) and cirrhosis (HR 17.470, 95% CI 5.081-60.063; P < 0.001) were those for developing HCC. CONCLUSIONS: In the era of antiviral therapy, overall clinical courses have been much improved since introduction of lamivudine in 1999. However, patients with older age or cirrhosis are still subject to HCC development despite appropriate antiviral therapy, necessitating cautious surveillance.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1005~1011-
dc.relation.isPartOfJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAge Factors-
dc.subject.MESHAntiviral Agents/therapeutic use*-
dc.subject.MESHCarcinoma, Hepatocellular/epidemiology-
dc.subject.MESHCarcinoma, Hepatocellular/etiology-
dc.subject.MESHCarcinoma, Hepatocellular/prevention & control-
dc.subject.MESHDisease Progression-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHGuanine/analogs & derivatives-
dc.subject.MESHGuanine/therapeutic use-
dc.subject.MESHHepatitis B, Chronic/complications-
dc.subject.MESHHepatitis B, Chronic/drug therapy*-
dc.subject.MESHHepatitis B, Chronic/virology-
dc.subject.MESHHumans-
dc.subject.MESHLamivudine/therapeutic use*-
dc.subject.MESHLiver Cirrhosis/epidemiology-
dc.subject.MESHLiver Cirrhosis/etiology-
dc.subject.MESHLiver Cirrhosis/prevention & control-
dc.subject.MESHLiver Neoplasms/epidemiology-
dc.subject.MESHLiver Neoplasms/etiology-
dc.subject.MESHLiver Neoplasms/prevention & control-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHThymidine/analogs & derivatives-
dc.subject.MESHThymidine/therapeutic use-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.titleLong-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Preventive Medicine (예방의학)-
dc.contributor.googleauthorYoon Hea Park-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJa Kyung Kim-
dc.contributor.googleauthorHyeon Chang Kim-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorSeung Hwan Shin-
dc.contributor.googleauthorKyu Yeon Hahn-
dc.contributor.googleauthorSang Hoon Ahn-
dc.identifier.doi10.1111/jgh.12478-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02226-
dc.contributor.localIdA04268-
dc.contributor.localIdA04269-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA00852-
dc.contributor.localIdA01142-
dc.contributor.localIdA01605-
dc.contributor.localIdA01675-
dc.contributor.localIdA02122-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ01417-
dc.identifier.eissn1440-1746-
dc.identifier.pmid24325579-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1111/jgh.12478/abstract-
dc.subject.keywordantiviral therapy-
dc.subject.keywordchronic hepatitis B-
dc.subject.keywordcirrhosis-
dc.subject.keyworddecompensation-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordprognosis-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.alternativeNameHahn, Kyu Yeon-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNameKim, Ja Kyung-
dc.contributor.alternativeNameKim, Hyeon Chang-
dc.contributor.alternativeNamePark, Yoon Hea-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameShin, Seung Hwan-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorHahn, Kyu Yeon-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorKim, Ja Kyung-
dc.contributor.affiliatedAuthorKim, Hyeon Chang-
dc.contributor.affiliatedAuthorPark, Yoon Hea-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorShin, Seung Hwan-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.rights.accessRightsfree-
dc.citation.volume29-
dc.citation.number5-
dc.citation.startPage1005-
dc.citation.endPage1011-
dc.identifier.bibliographicCitationJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.29(5) : 1005-1011, 2014-
dc.identifier.rimsid54293-
dc.type.rimsART-
Appears in Collections:
6. Others (기타) > Dept. of Health Promotion (건강의학과) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.